Unknown

Dataset Information

0

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses.


ABSTRACT: There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64??M for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing.

SUBMITTER: Makarov VA 

PROVIDER: S-EPMC4600222 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses.

Makarov Vadim A VA   Braun Heike H   Richter Martina M   Riabova Olga B OB   Kirchmair Johannes J   Kazakova Elena S ES   Seidel Nora N   Wutzler Peter P   Schmidtke Michaela M  

ChemMedChem 20150810 10


There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruse  ...[more]

Similar Datasets

| S-EPMC6559632 | biostudies-literature
| S-EPMC5554915 | biostudies-literature
| S-EPMC5415599 | biostudies-literature
| S-EPMC4613828 | biostudies-literature
| S-EPMC5720685 | biostudies-literature
| S-EPMC6547740 | biostudies-literature
| EMPIAR-10199 | biostudies-other
| S-EPMC7269450 | biostudies-literature
| S-SCDT-10_1038-S44321-024-00143-W | biostudies-other
| S-EPMC4576193 | biostudies-literature